Symptoms and General Pathology

All Conditions

Nutritional and Metabolic Diseases

Neoplasms

Blood and Lymph Conditions

Rare Diseases

Syndrome

Iron Overload

Preleukemia

Myelodysplastic Syndromes

Primary Myelofibrosis

Bone Marrow Diseases

Hematologic Diseases

Precancerous Conditions

Myeloproliferative Disorders

Chronic Myeloproliferative Disorders

Micronutrients

All Drugs and Chemicals

Iron

patients with in iron overloaded MDS patients (low and high risk ), and also patients with primary myelofibrosis. The risk stratification of these patients will be calculated according to the IPSS (International Prognostic Scoring System).

Ghoti Hussam, MD

Recently, it has been demonstrated that iron overload is associated with the appearance of labile plasma iron (LPI).

LPI is redox active and is rapidly taken up by cells, leading to a rise in the labile iron pool (LIP) and catalyzing generation of reactive oxygen species (ROS), which can lead to cellular damage.

The LPI data are mostly derived from thalassemia iron overload research , however, there are a few data describing LPI and its correlations with the classical iron overload parameters (ferritin, TSAT) in acute anemias such as MDS Therefore we are going to assess LPI in iron overloaded myelodysplastic syndromes (MDS) (low and high risk) and primary myelofibrosis, in order to assess whether it can be used as alternative to the routinely used parameters; TSAT and ferritin levels.

Approximately 60-80% of patients with myelodysplastic syndromes (MDS) present with symptomatic anemia and 80-90%, of these, will require red blood cell (RBC) transfusions. Excess transfusional iron causes iron overload (IO) which is characterized by elevated serum ferritin (\> 1000ng/ml) and transferrin saturation (TSAT \> 50%) levels.

Assessment of IO using serum ferritin and TSAT levels is not accurate enough and this is due to changes in serum ferritin and TSAT during any inflammatory condition.

Since serum ferritin is considered as a positive acute phase reactant and therefore inflammatory state can lead to an increase in serum ferritin levels and so does not reflect the exact amount of iron overload.

In contrast TSAT can decrease during inflammation and in addition it follows diurnal variations.The aim of our present study is to asses the levels of LPI in patients with in iron overloaded MDS patients (low and high risk), and also patients with primary myelofibrosis, in order to find out any laboratory correlations between LPI, TSAT and srum ferritin levels.

Methods:

The study will contain 50 patients low+high risk MDS patients and patients with primary myelofibrosis with iron overloaded. The risk stratification of these patients will be calculated according to the WPSS (WHO adapted Prognostic Scoring System)

After ICF (Informed Consent Form) has been signed by the patients the following laboratory tests will be taken once during the study:

* Ferritin (local laboratory)
* Transferrin Saturation (local laboratory)
* CRP (local laboratory)
* LPI (feROS™ eLPI from Aferrix Ltd., Tel- Aviv, Israel)

Assessment of Labile Plasma Iron (LPI) in Myelodysplastic Syndromes (MDS) and Primary Myelofibrosis

Assessment of Labile Plasma Iron (LPI) as an Alternative Parameter for Iron Overload in MDS and Primary Myelofibrosis Patients With Iron Overload and Its Correlations With the Classical Iron Overload Parameters.

The blood samples should be taken at least one week apart from last blood transfusion.

In case of infection or acute inflammation , blood samples should be taken only one week after resolution of these conditions.

Wolfson Medical Center

Dr' Ghoti Hussam

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Assessment of Labile Plasma Iron (LPI) in Myelodysplastic Syndromes (MDS) and Primary Myelofibrosis	NCT01331603	Myelodysplastic... Primary Myelofi...		18 Years -	Wolfson Medical Center
Assessment of Labile Plasma Iron (LPI) in Myelodysplastic Syndromes (MDS) and Primary Myelofibrosis	NCT01331603	Myelodysplastic... Primary Myelofi...		18 Years -	Wolfson Medical Center

Spots Global Cancer Trial Database for low+high risk mds patients